Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer

Cancer Research

Volumn 60, Issue 4, 2000, Pages 1062-1069

  Lehman, Teresa A ^a   Haffty, Bruce G ^b   Carbone, Christopher J ^d   Bishop, Lisa R ^a   Gumbs, Andrew A ^b   Krishnan, Shiva ^c   Shields, Peter G ^c   Modali, Rama ^a   Turner, Bruce C ^d  

^a BioServe Biotechnologies Ltd   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; GENE MUTATION; GERM LINE; HUMAN; HUMAN CELL; INTRON; MUTATION RATE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; FEMALE; GENES, P53; GENOTYPE; GERM-LINE MUTATION; HUMANS; INTRONS; LI-FRAUMENI SYNDROME; MIDDLE AGED;

EID: 0034652588     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumor suppressor gene. Nature (Lond.), 351: 453-456, 1991.
2. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
3. Volgelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
4. Lowe, S. W., Ruley, H. E., Jacks, T., and Houseman. D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
5. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fischer, D. E., Houseman, D. E., and Jacks. T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266; 807-810, 1994.
6. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
7. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-852, 1993.
8. Santibanez-Koref, M. F., Birch, J. M., Hartley, A. L., Jones, P. H., Craft, A. W., Eden, T., Crowther, D., Kelsey, A. M., and Harris, M. p53 germline mutations in Li-Fraumeni syndrome. Lancet, 338: 1490-1491, 1991.
9. Malkin, D., Li., FP., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., and Tainsky, M. A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
10. Varley, J. M., Evans, D. G. R., and Birch, J. M. Li-Fraumeni syndrome: a molecular and clinical review. Br. J. Cancer, 76: 1-14, 1997.
11. Toguchida, J., Yamaguchi, T., Dayton, S. H., Beauchamp, R. L., Herrera, G. E., Ishizaki, K., Yamamuro, T., Meyers, P. A., Little, J. B., Sasaki, M. S., Weichselbaum, R. R., and Yandell, D. W. Prevalence and spectrum of germ-line mutations of the p53 gene among patients with sarcoma. N. Engl. J. Med., 326: 1301-1308, 1992.
12. Buller, R. E., Skilling, J. S., Kaliszewski, S., Niemann, T., and Anderson, B. Absence of significant of germ line p53 mutations in ovarian cancer patients. Gynecol. Oncol., 58: 368-374, 1995.
13. Prosser, J., Elder, A., Condie, A., MacFadyen, I., Steel, C. M., and Evan, H. J. Mutations in p53 do not account for heritable breast cancer: a study in five affected families. Br. J. Cancer, 63: 181-184, 1991.
14. Preudhomme, C., Fenaux, P., Peyrat, J. P., Fournier, J., Bonneterre, J., and Vennin, P. Absence of germline mutations of exons 5 to 8 of the p53 gene in 26 breast cancer families from the north of France. Eur. J. Cancer 29A: 1476-1478, 1993.
15. Borreson, A. L., Andersen, T. I., Garber, J., Barbier-Piraux, N., Thorlacius, S., Eyfjord, J., Ottestad, L., Smith-Sorensen, B., Hovig, E., and Malkin, D. Screening for germline TP53 mutations in breast cancer patients. Cancer Res., 52: 3234-3236, 1992.
16. Warren, W., Eeles, R. A., Ponder, B. A., Easton, D. F., Averill, D., Ponder, M. A., Anderson, K., and Evans, A. M., DeMars, R., and Love, R. No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. Oncogene, 7: 1043-1046, 1992.
17. Varley, J. M., McGown, G., Thomcroft, M., Santibanez-Koref, M. F., Kelsey, A. M., Tricker, K. J., Evans, D. G., and Birch, J. M. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res., 57: 3245-3252, 1997.
18. Lozano, G., and Levine, A. J. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol. Carcinog., 4: 3-9, 1991.
19. Varley, J. M., Chapman, P., McGowen, G., Thorncroft, M., White, G. R., Greaves, M. J., Scott, D., Spreadborough, A., Tricker, K. J., Birch, J. M., Evans, D. G., Reddel, R. Camplejohn, R. S., Burn, J., and Boyle, J. M. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family. Oncogene, 16: 3291-3298, 1998.
20. Orita, M., Suzuki, Y., Sekiya, T., and Hayashi, K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5: 874-879, 1989.
21. Lehman, T. A., Bennett, W. P., Metcalf, R. A., Welsh, J. A., Ecker, J., Modali, R. V., Ullrich, S., Romano, J. W., Appella, E., Testa, J. R., Gerwin, B. I., and Harris, C. C. p53 mutations, ras mutations, and p53-heat shock 70 proteins complexes in human lung carcinoma cell lines. Cancer Res., 51: 4090-4096, 1991.
22. Chee, M., Yang, R., Hubbell, E., Berno, A., Huang, X. C., Stern, D., Winkler, J., Lockhart, D. J., Morris, M. S., and Fodor, S. P. Accessing genetic information with high-density DNA arrays. Science (Washington DC), 274: 610-614, 1996.
23. Shattuck-Eidens, D., Oliphant, A., McClure, M., McBride, C., Gupte, J., Rubano, T., Pruss, D., Tavtigian, S. V., Teng, D. H., Adey, N., et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. J. Am. Med. Assoc., 278: 1242-1250, 1997.
24. Bull, E. K., Chakrabarty, S., Brodsky, I., and Haines, D. S. mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells. Oncogene, 16: 2249-2257, 1998.
25. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. Suppression of human coloreclal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
26. Turner, B. C., Haffty, B. G., Narayanan, L., Yuan, J., Havre, P. A., Gumbs, A. A., Kaplan, L., Burgaud, J. L., Carter, D., Baserga, R., and Glazer, P. M. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res., 57: 3079-3083, 1997.
27. Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, L., Rebbeck, T., and Weber, B. L. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med., 336: 1409-1415, 1997.
28. Langston, A. A., Malone, K. E., Thompson, J. D., Daling, J. R., and Ostrander, E. A. BRCA1 mutations in a population-based sample of young women with breast cancer. N. Engl. J. Med., 334: 137-142, 1996.
29. Krainer, M., Silva-Arrieta, S., Fitzgerald, M. G., Shimada, A., Ishioka, C., Kanamaru, R., MacDonald, D. J., Unsal, H., Finkelstein, D. M., Bowcock, A., Isselbacher, K. J., and Haber, D. A. Differential contributions of BRCA1 and BRCA2 to early onset breast cancer. N. Engl. J. Med., 336: 1416-1421, 1997.
30. Eeles, R. A., Stratton, M. R., Goldgar, D. E., and Easton, D. F. The genetics of familial breast cancer and their practical implications. Eur. J. Cancer, 30: 1383-1390, 1991.
31. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2: 811-814, 1996.
32. Bergh, J., Norberg, T., Sjogren, S., Lindgren, A., Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med. 1: 1029-1034, 1995.
33. Barnes, D. M., Hanby, A. M., Gillett, C. E., Mohammed, S., Hodgson, S., Leigh, I. M., Purkis, T., MacGeoch, C., Spurr, N. K., Bartek, J., Vojtesek, B., Picksley, S. M., and Lane, D. P. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet, 340: 259-263, 1992.
34. Sun, X. F., Johannsson, O., Hakansson, S., Sellberg, G., Nordenskjold, B., Olsson, H., and Borg, A. A novel p53 germline alteration identified in a late onset breast cancer kindred. Oncogene 13: 407-411, 1996.
35. Delia, D., Goi, K., Mizutani, T., Yamada, T., Aiello, A., Fontanella, E., Lamorte, G., Iwata, S., Ishioka, C., Krajewski, S., Reed, J. C., and Pierotti, M. A. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene, 14: 2137-2147, 1997.
36. Hillebrandt, S., Streffer, C., Demidchik, E. P., Biko, J., and Reiners, C. Polymorphisms in the p53 gene in thyroid tumors and blood samples of children from areas in Belarus. Mutat. Res., 381: 201-207, 1997.
37. Avigad, S., Barel, D., Blau, O., Malka, A., Zoldan, M., Mor, C., Fogel, M., Cohen, I. J., Stark, B., Goshen, Y., Stein, J., and Zaizov, R. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene, 14: 1541-1545, 1997.
38. Barel, D., Avigad, S., Mor, C., Fogel, M., Cohen, I. J., and Zaizov, R. A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family. Cancer Genet. Cytogenet 103: 1-6, 1998.
39. Peller, S., Kopilova, Y., Slutzki, S., Halevy, A., Kvitko, K., and Rotter, V. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol., 14: 983-990, 1995.
40. McDaniel, T., Carbone, D., Takahashi, T., Chumakov, P., Chang, E. H., Pirollo, K. F., Yin, J., Huang, Y., and Meltzer, S. J. The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res., 19: 4796-4802, 1991.
41. Magewu, A., and Jones, P. A. Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer. Mol. Cell Biol., 14: 4225-4232, 1994.